TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT04977453: GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors

Sponsor: GI Innovation, Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 317 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT04977453 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04977453 Rescue Dossier →